ARTICLE | Company News
BioTransplant restructures
November 15, 2002 8:00 AM UTC
BTRN said it plans to partner, divest or close all programs and assets aside from MEDI-507. Last month, BTRN partner MedImmune (MEDI)delayed by about a year the start of Phase III testing of their MEDI-507 antibody to treat psoriasis. Also, BTRN gave all employees a tentative notice of future termination. ...